Sunday November 22 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Biocept Incorporated

Privately held Biocept was founded in 1997 and is based in Carlsbad, California near San Diego.

Biocept is emerging as a leader in the development and commercialization, in part through partners, of Next Generation Microarrays for Genomics and Proteomics™. Biocept’s proprietary platform technology is based on novel hydrogel polymers. The resulting three-dimensional microarrays have very high sensitivity, excellent precision and a broad dynamic range. Biocept has already developed several assay formats for the analysis of samples containing nucleic acids or proteins. Biocept has collaborations with investigators at leading research organizations for prototype microarrays to monitor the expression of apoptosis-related genes.



Life Sciences applications of Biocept’s genomic and proteomic microarrays include pharmaceutical research and development [e.g. target identification and validation, expression profiling, pathway analysis, high throughput screening, ADMET studies, and detection of single nucleotide polymorphisms (SNP's)] and clinical diagnostics.



Science & Technology:



Successful genomic and proteomic research requires tools that can rapidly and accurately provide results. While gene expression profiling is frequently the first step, protein expression may ultimately be more important, since proteins are the targets for most drugs. Gene expression does not always correlate well with the amount or activity of expressed proteins. In addition, protein diversity and activity results from alternative splicing at the messenger RNA level and by post-translational modifications such as phosphorylation and glycosylation. Several forms of a single protein may have important roles either as targets for drug discovery or as indicators of toxicity. These relationships demonstrate the crucial importance of proteomics in drug discovery.



Biocept's platform technology uses proprietary hydrogel polymers to create three-dimensional microarrays. Biocept prints microdroplets in an array on a treated glass slide. Each microdroplet contains a large number of molecules of a single probe, uniformly dispersed within and covalently bound to the hydrogel matrix. Key features of Biocept's microarrays are:



§ Versatile-useful for genomic and proteomic applications-



Biocept has developed and demonstrated the utility of genomic and proteomic microarrays in formats suitable for many life sciences applications.



§ High probe density provides high precision and broad dynamic range-



The higher probe density provides a lower coefficient of variation and broader dynamic range than conventional two-dimensional microarrays.



· Aqueous environment allows biomolecular probes to retain native conformation and activity-



Probes tethered within a hydrogel microdroplet retain their native three-dimensional configuration and activity, improving interaction with targets in the sample.



§ Readily manufactured-



Microdroplets about 300 microns in diameter and 30 microns thick are deposited as an array on a treated glass slide.



Biocept’s platform technology is protected by issued or pending patents in all major pharmaceutical markets.



Commercialization Strategy:



Biocept is establishing corporate partnerships and other collaborations to accelerate the development, commercialization and utilization of microarrays based on its technology. This includes partnerships with Pharmaceutical/Biotech companies for research and development, collaborations with Life Science Reagents companies, partnerships for clinical diagnostics, and partnerships to enhance technology development and commercialization.


Contact Details:
2151 Las Palmas Drive, Suite C
Carlsbad
CA
92009
United States of America
Tel:(760) 804-9580 x15
Fax:(760) 804-6238
Email:kbrown@biocept
WWW:

www.biocept.com/




Loading...

Biocept Incorporated Clinical Trials:

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Biocept Incorporated Patents:

US Patent No.Title
7595157 Microarrays utilizing hydrogels
6433134 Peptide nucleic acid precursors and methods of preparing same
7172866 Methods and gel compositions for encapsulating living cells and organic molecules
7198901 Reflective substrate and algorithms for 3D biochip
7217520 Microwell biochip

View more Biocept Incorporated patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 868 times since April 2007, the link to the organisation's website has been followed 125 times

Search for more companies in Carlsbad

Search for more companies in CA



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Biocept Incorporated

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.